Biblio Discovery — Demo Discovery Service

13 results for "Omar Mamlouk"

Showing 1–13 · 0.47 seconds · RSS

  1. Journal Article

    Lupus-Like Glomerulonephritis Associated With Regorafenib, a Multikinase Inhibitor

    Anna Strasma; Howard Coke; Omar Mamlouk et al.

    Kidney Medicine, Vol. 3 No. 2 · 2021 · English · DOAJ Scopus

    Drug-induced lupus glomerular diseases have historically been associated with hydralazine, but new drugs that modify the growth, metabolism, and immunity of cells are increasingly found to cause glomerular disease. This includes anti–tumor necrotic factor and other antibody agents used in cancer…

  2. Journal Article

    Nilotinib-Induced Unilateral Renal Artery Stenosis: A Complication Prompting Treatment-Free Remission in Chronic Myeloid Leukemia

    Mitchell C. Boshkos; Humberto R. Nieves-Jiménez; Parin H. Thakkar et al.

    Case Reports in Oncological Medicine, Vol. 2025 · 2025 · English · DOAJ Scopus

    Renal artery stenosis (RAS) is a rare but significant vascular complication associated with nilotinib therapy for chronic myeloid leukemia (CML). We present the case of a woman in her mid-70s on long-term nilotinib who developed this adverse event. The patient presented with a progressive…

  3. Journal Article

    Checkpoint inhibitor-related renal vasculitis and use of rituximab

    Noha Abdel-Wahab; Ala Abudayyeh; Omar Mamlouk et al.

    Journal for ImmunoTherapy of Cancer, Vol. 8 No. 2 · 2020 · English · DOAJ Scopus

    The percentage of patients with cancer eligible for checkpoint inhibitor (CPI) therapy has increased rapidly over the past few years and approaches 45%. As a result, more cases of CPI-related nephrotoxicity, including a rare subset with vasculitis, are being reported. To elucidate the clinical…

  4. Journal Article

    Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab

    Cassian Yee; Ala Abudayyeh; Maen Abdelrahim et al.

    Journal for ImmunoTherapy of Cancer, Vol. 8 No. 2 · 2020 · English · DOAJ Scopus

    The same mechanisms that mediate antitumor immunity from checkpoint inhibitors (CPIs) can also lead to unintended targeting of normal tissues, characterized as immune-related adverse events (irAEs). Those with pre-existing autoimmune disease are believed to be particularly vulnerable for…

  5. Journal Article

    Potential Benefit of Sodium-Glucose Cotransporter 2-Inhibitors in Cisplatin-Associated Nephrotoxicity Among Patients With Cancer Having Diabetes Mellitus

    Juan J. Cintrón-García; Maulinkumar Patel; Clark R. Andersen et al.

    Kidney International Reports, Vol. 11 No. 6 · 2026 · English · DOAJ Scopus

    Introduction: Cisplatin is often nephrotoxic, frequently causing treatment interruptions or discontinuation. Mitigation includes dose adjustments, hydration, and supplemental magnesium. Sodium-glucose cotransporter-2 inhibitors (SGLT2is) may protect the kidneys by reducing tubular cells’ cisplatin…

  6. Journal Article

    Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis

    Maen Abdelrahim; Omar Mamlouk; Heather Lin et al.

    OncoImmunology, Vol. 10 No. 1 · 2021 · English · DOAJ Scopus

    Background: The incidence of renal immune-related adverse events (irAEs) is reported to be 3.8%, with varied definitions of acute kidney injury (AKI). This study reports a 10-year experience at MD Anderson Cancer Center of patients diagnosed with melanoma and treated with immune checkpoint…

  7. Journal Article

    Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis

    Jamie S. Lin; Omar Mamlouk; Umut Selamet et al.

    OncoImmunology, Vol. 10 No. 1 · 2021 · English · DOAJ Scopus

    Acute tubular interstitial nephritis (ATIN) is the most frequently reported pathology in patients with checkpoint inhibitor (CPI) induced acute kidney injury (AKI). Glucocorticoid (GC) therapy and discontinuation of CPI are the mainstay of treatment to prevent permanent renal dysfunction and…

  8. Journal Article

    Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience

    Omar Mamlouk; Umut Selamet; Shana Machado et al.

    Journal for ImmunoTherapy of Cancer, Vol. 7 No. 1 · 2019 · English · DOAJ Scopus

    Abstract Rationale & Objective The approved therapeutic indication for immune checkpoint inhibitors (CPIs) are rapidly expanding including treatment in the adjuvant setting, the immune related toxicities associated with CPI can limit the efficacy of these agents. The literature on the…

  9. Journal Article

    Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study

    Frank B. Cortazar; Zoé A. Kibbelaar; Ilya G. Glezerman et al.

    Journal of the American Society of Nephrology · 2020 · English · OpenAlex Scopus

    Significance Statement Kidney toxicity from use of immune checkpoint inhibitors is being recognized as an increasingly frequent complication of treatment. However, existing data on immune checkpoint inhibitor–associated AKI have been limited to small, mostly single-center studies. In this…

  10. Journal Article Full text

    Acute kidney injury in patients treated with immune checkpoint inhibitors

    Shruti Gupta; Samuel Short; Meghan E. Sise et al.

    Journal for ImmunoTherapy of Cancer · 2021 · English · OpenAlex Scopus

    BACKGROUND: Immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer. METHODS: We collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemporaneously but who did not develop ICPi-AKI…

    Also available at: DOAJ

  11. Journal Article

    Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI

    Joe-Elie Salem; Enriqueta Felip; Shuchi Anand et al.

    Journal for ImmunoTherapy of Cancer, Vol. 10 No. 9 · 2022 · English · DOAJ Scopus

    Background Corticosteroids are the mainstay of treatment for immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI), but the optimal duration of therapy has not been established. Prolonged use of corticosteroids can cause numerous adverse effects and may decrease progression-free…